Revisión Bibliográfica

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Appl Immunohistochem Mol Morphol 
Volume 27, Number 10, November/December 2019
Since 2014, programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck can- cer, classical Hodgkin lymphoma, colorectal cancer, gastro- esophageal cancer, hepatocellular cancer, and other solid tumors.

Leer completo »

Retos Diagnóstico

Caso de Ginecopatología

Dra. García Kamermann F, Falcón F, Sciaccaluga D, Cardinal L, Díaz L.
Departamento de Anatomía Patológica, División Patología Ginecológica.
Hospital de Clínicas “José de San Martín”,
Ciudad Autónoma de Buenos Aires. Argentina.

Leer completo »

Publicaciones Recomendadas